Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells $243,474.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 3,162 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the sale, the senior vice president owned 75,534 shares in the company, valued at approximately $5,816,118. This represents a 4.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock traded down $1.23 during trading hours on Tuesday, reaching $74.53. The stock had a trading volume of 526,173 shares, compared to its average volume of 341,915. The stock’s fifty day simple moving average is $81.00 and its 200 day simple moving average is $79.18. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 12 month low of $70.15 and a 12 month high of $99.50. The firm has a market capitalization of $1.70 billion, a PE ratio of 16.06 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. During the same quarter in the previous year, the company earned $1.80 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on ANIP. Canaccord Genuity Group decreased their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Guggenheim lowered their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $105.83.

Hedge Funds Weigh In On ANI Pharmaceuticals

Large investors have recently modified their holdings of the company. KBC Group NV purchased a new stake in ANI Pharmaceuticals in the first quarter worth approximately $28,000. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals during the first quarter worth approximately $28,000. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth approximately $48,000. Finally, State of Wyoming bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $50,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.